People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Civitas Therapeutics, Inc. | — | Biotechnology | Series C | $117.8M | $2.3B | 2010 |
| Palyon Medical Corp | — | Biotechnology | Series B | $45.0M | $952.5M | 2009 |
| Velicept Therapeutics, Inc. | — | Pharmaceuticals | Series B | $39.9M | $204.0M | 2018 |
Aidan King at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Aidan King on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Hirsch | 2 | 16 |
| James Walker | 1 | 16 |
| Timothy Shannon | 1 | 9 |
| Michael Liang | 1 | 9 |
| Stephen Tullman | 1 | 7 |
| Rob Hopfner | 1 | 6 |
| Daniel Omstead | 1 | 4 |
| Andrea Franz | 1 | 4 |
| Mark Iwicki | 1 | 4 |
| Douglas Gessl | 1 | 4 |
| Glenn Batchelder | 1 | 4 |
| David Present | 1 | 3 |
| Glen Kashuba | 1 | 3 |
| James C. Walker | 1 | 3 |
| Martin Freed | 1 | 3 |
| Scott S. Morenstein | 1 | 3 |
| Cherine Plumaker | 1 | 3 |
| Scott Morenstein | 1 | 2 |
| Bryan Stuart | 1 | 2 |
| Mary Taylor | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.